Kaplan-Meier curves showing effect of DNMT3A VAF and double DNMT3A mutations in normal karyotype patients receiving induction chemotherapy. (A-B) Effect of high DNMT3A VAF on (A) EFS (14.1 months, n = 33 vs 56.8 months, n = 43; P = .0154) and (B) OS (18.3 months, n = 33 vs not reached, n = 43; P = .0011). (C-D) Effect of double DNMT3A mutations on (E) EFS (5.4 months, n = 8 vs 28.2 months, n = 68; P = .0190) and (F) OS (9.3 months, n = 8 vs 47.0 months, n = 68; P = .0156) in the entire cohort. Values were generated using the log-rank test.